Risk-Based Monitoring Insights From The Industry: Dr. Peter Schiemann
In the fourth installment of the CluePoints Risk-Based Monitoring Q&A series, we spoke to Dr. Peter Schiemann, Managing Partner and Co-Founder of Widler & Schiemann, who
How Will Risk-Based Monitoring Coexist With Other Clinical Trial Technology?
We’ve been really enjoying hearing your thoughts on the latest Risk-Based Monitoring hot topics over the last few weeks, so thank you to everyone who
Risk-Based Monitoring Insights From The Industry: Karen Fanouillere
Part Three In the third of an eight-part Q&A series which aims to explore some of the current hot topics in Risk-Based Monitoring (RBM), CluePoints has
Risk-Based Monitoring Insights And Strategies From The Industry: Adam Butler
Part Two Recently, CluePoints has been taking time out with some of our valued partners to discuss hot topics in Risk-Based Monitoring (RBM). Here, in
Is It Too Soon To Define Best Practice When It Comes To The Practical Implementation Of Risk-Based Monitoring?
Last week CluePoints launched its eight-part Q&A blog series which aims to explore the current talking points in Risk-Based Monitoring (RBM). We’ve been gathering insights
Risk-Based Monitoring Insights From The Industry: Craig Serra
Part One In the first of an eight-part Q&A series which aims to explore some of the current hot topics in Risk-Based Monitoring (RBM), CluePoints
RACT Clinical Trials: How To Deploy Risk Assessment Categorization Effectively
The move towards risk-based monitoring promises to bring clinical trials into the 21st century by driving the efficient delivery of life-changing new medicines. But while the
Transcelerate’s Latest Paper – “Detecting Data Quality Issues In Clinical Trials: Current Practices And Recommendations”
Pressure is growing for sponsors to implement robust controls to identify data quality issues that may impact trial outcomes, and this is understandable given the
Want Full Control Of Your Risk-Based Monitoring Analyses?
CluePoints introduces a web-based Central Statistical Monitoring (CSM) SaaS solution As you may have read on a few industry blogs, we recently launched a Software-as-a-Service (SaaS)
The Evolution Of CluePoints’ SMART Engine
Regarding CluePoints’ statistical approach to risk-based monitoring in clinical trials, we are often asked questions about sample size, such as: “How many subjects are needed per site to
